Download PDF
Fortschr Neurol Psychiatr 2001; 69(3): 116-137
DOI: 10.1055/s-2001-12278
ORIGINALARBEIT
Georg Thieme Verlag Stuttgart · New York

Zur Pathophysiologie der Gewichtsregulation im Rahmen der Therapie mit Psychopharmaka

T. Kraus, U. Zimmermann, A. Schuld, M. Haack , D. Hinze-Selch1 , T. Pollmächer
  • Max-Planck-Institut für Psychiatrie, München (Direktor: Prof. Dr. Dr. F. Holsboer)
  • 1Abteilung für Psychiatrie und Psychotherapie der Christian-Albrechts-Universität, Kiel (Direktor: Prof. Dr. J. Aldenhoff)
Further Information

Publication History

Publication Date:
31 December 2001 (online)

Also available at
    Permissions and Reprints

Zusammenfassung:

Gewichtsveränderungen unter psychopharmakologischer Therapie sind seit langem bekannt und werden seit den 50er Jahren erforscht. Sie treten überwiegend in Form von Gewichtszunahmen auf. Die klinische Relevanz ergibt sich zum einen aus einer erhöhten allgemeinen Morbiditätsrate und zum anderen aus einer Gefährdung der Therapie-Compliance. Gewichtsanstiege finden sich bei Patienten während der Behandlung mit Psychopharmaka unterschiedlichster chemischer Struktur und aus den verschiedensten Substanzklassen. Als Ursachen werden schon lange Medikamenteneffekte auf verschiedene Neurotransmitter-Systeme, insbesondere blockierende Wirkungen auf Serotonin- und Histamin-Rezeptoren, diskutiert. Erst in den letzten Jahren wird zunehmend erforscht, welche Rolle endokrine Faktoren spielen. Hierbei zeichnet sich eine besonders wichtige Rolle für das im Fettgewebe produzierte Hormon Leptin ab, welches dem zentralen Nervensystem die Größe der peripheren Fettspeicher signalisiert, und das wohl die entscheidende periphere Regelgröße für die langfristige Gewichtsregulierung darstellt. Darüber hinaus deuten jüngste Befunde darauf hin, dass auch Immunmediatoren, und unter diesen insbesondere das proinflammatorische Zytokin Tumornekrosefaktor-α (TNF-α) und die löslichen TNF-Rezeptoren, an psychopharmaka-induzierten Veränderungen von Appetit und Gewicht ursächlich beteiligt sind. Veränderungen des TNF-Systems treten sogar schon deutlich vor der Gewichtszunahme auf, so dass ihnen eventuell ein prädiktiver Wert zukommt. Die Möglichkeiten zur Prophylaxe und Therapie psychopharmaka-induzierter Gewichtsanstiege umfassen einerseits psychotherapeutische und andererseits medikamentöse Maßnahmen. Zwar existiert eine Reihe strukturierter verhaltenstherapeutischer Programme, die gut zur Gewichtsreduktion geeignet sind, aber insbesondere bei schwer kranken psychiatrischen Patienten sind sie oft von nur geringgradiger Effizienz. Bezüglich der möglichen pharmakologischen Interventionen zeichnen sich vielversprechende Ansätze dadurch ab, dass in den letzten Jahren sowohl zentral als auch peripher wirksame Medikamente zur Gewichtsreduktion in die Klinik eingeführt wurden; allerdings liegen zu ihrer Verwendbarkeit im Bereich psychiatrischer Erkrankungen und zur Frage der pharmakokinetischen und pharmakodynamischen Interaktion mit Psychopharmaka bisher keine ausreichenden Daten vor.

On the Pathophysiology of Weight Regulation During Treatment with Psychotropic Drugs:

Weight changes during pharmacological treatment are a well-known phenomenon and they have been an object of research since the 1950's. Weight gain occurs during treatment with drugs of different chemical structures and is an important problem when patients are treated with antidepressants, antipsychotics, or mood stabilizers. The clinical relevance of drug-induced weight changes is due to increased rates of morbidity and reduced treatment compliance. Regarding the underlying causes, the important role of neurotransmitter systems and in particular the blockade of serotonin and histamine receptors has been discussed since decades. Only recently, however, research has been started on the effects of psychotropic agents on major neuroendocrine systems involved in appetite and weight regulation. These studies suggest that the fat-cell derived hormone leptin might play an important role. Leptin signals to the brain the size of the adipose tissue and is probably the most important peripheral signal for the long-term regulation of weight. In addition to the neuroendocrine systems, weight gain induced by psychotropic agents might also involve immune modulators, in particular the proinflammatory cytokine tumor-necrosis-factor-α (TNF-α) and soluble TNF-receptors. Some psychotropic agents influence the TNF system very rapidly, already prior to any obvious increases in weight. Hence, changes in the TNF-α system might be of predictive value for drug-induced weight gain. Strategies to minimize or to counteract weight gain induced by psychotropic agents include psychotherapeutic and pharmacological approaches. Although numerous psychotherapeutic approaches are available, they are only of limited usefulness in severely ill psychiatric patients. Fortunately, a number of promising pharmacological approaches to reduce weight have been introduced into clinical practice during the last years; however, so far there is no knowledge on pharmacodynamic and -kinetic interactions with psychotropic drugs, and there is no clinical data on the usefulness and safety of such drug combinations.

Literatur

  • 1 Mefferd R B, Labrosse E H, Gawienoski A M, Williams R J. Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics.  J Nerv Ment Di. 1958;  127 167-179
    PubMedGoogle Scholar
  • 2 Planansky K, Heilizer F. Weight changes in relation to the characteristic patients on chlorpromazine.  J Clin Exp Psychol. 1959;  20 53-57
    PubMedGoogle Scholar
  • 3 Fawcett J, Barkin R L. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression.  J Affect Disord. 1998;  51 267-285
    CrossrefPubMedGoogle Scholar
  • 4 Berken G H, Weinstein D O, Stern W C. Weight gain. A side-effect of tricyclic antidepressants.  J Affect Disord. 1984;  7 133-138
    CrossrefPubMedGoogle Scholar
  • 5 Garland E J, Remick R A, Zis A P. Weight gain with antidepressants and lithium.  J Clin Psychopharmacol. 1988;  8 323-330
    PubMedGoogle Scholar
  • 6 Allison D B, Mentore J L, Heo M, Chandler L P, Cappelleri J C, Infante M C, Weiden P J. Antipsychotic-induced weight gain: a comprehensive research synthesis.  Am J Psychiatry. 1999;  156 1686-1696
    PubMedGoogle Scholar
  • 7 Sussman N, Ginsberg D L. Weight effects of nefazodone, bopropion, mirtazapine, and venlafaxine: A review of the available evidence.  Primary Psychiatry. 2000;  7 33-48
    PubMedGoogle Scholar
  • 8 Willett W C, Dietz W H, Colditz G A. Guidelines for healthy weight.  N Engl J Med. 1999;  341 427-434
    CrossrefPubMedGoogle Scholar
  • 9 Bech P, Vendsborg P B, Rafaelsen O J. Lithium maintenance treatment of manic-melancholic patients: its role in the daily routine.  Acta Psychiatry Scand. 1976;  53 70-81
    PubMedGoogle Scholar
  • 10 Leadbetter R, Shutty M, Pavalonis D, Vieweg V, Higgins P, Downs M. Clozapine-induced weight gain: prevalence and clinical relevance.  Am J Psychiatry. 1992;  149 68-72
    PubMedGoogle Scholar
  • 11 Bai Y M, Lin C C, Chen J Y, Lin C Y. Weight gain among patients on clozapine.  Psychiatr Serv. 1999;  50 704-705
    PubMedGoogle Scholar
  • 12 Umbricht D S, Pollack S, Kane J M. Clozapine and weight gain.  J Clin Psychiatry. 1994;  55 Suppl B 157-160
    PubMedGoogle Scholar
  • 13 Bustillo J R, Buchanan R W, Irish D, Breier A. Differential effect of clozapine on weight: a controlled study.  Am J Psychiatry. 1996;  153 817-819
    CrossrefPubMedGoogle Scholar
  • 14 Kupfer D J, Coble P A, Rubinstein D. Changes in weight during treatment for depression.  Psychosom Med. 1979;  41 535-544
    PubMedGoogle Scholar
  • 15 Roose S P. Tolerability and patient compliance.  J Clin Psychiatry. 1999;  60 Suppl 17 14-17
    PubMedGoogle Scholar
  • 16 Tuomisto L. Regulation of feeding behavior, with special reference to histamine.  J Physiol Pharmacol. 1994;  45 469-477
    PubMedGoogle Scholar
  • 17 Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management.  Acta Psychiatr Scand. 1999;  100 3-16
    PubMedGoogle Scholar
  • 18 Yim G K, Lowy M T. Opioids, feeding, and anorexias.  Fed Proc. 1984;  43 2893-2897
    PubMedGoogle Scholar
  • 19 Zimmermann U, Rechlin T, Plaskacewicz G J, Barocka A, Wildt L, Kaschka W P. Effect of naltrexone on weight gain and food craving induced by tricyclic antidepressants and lithium: an open study.  Biol Psychiatry. 1997;  41 747-749
    PubMedGoogle Scholar
  • 20 Casanueva F F, Dieguez C. Neuroendocrine regulation and actions of leptin.  Front Neuroendocrinol. 1999;  20 317-363
    CrossrefPubMedGoogle Scholar
  • 21 Sakurai T. Orexins and orexin receptors: implication in feeding behavior.  Regul Pept. 1999;  85 25-30
    CrossrefPubMedGoogle Scholar
  • 22 Meister B. Control of food intake via leptin receptors in the hypothalamus.  Vitam Horm. 2000;  59 265-304
    PubMedGoogle Scholar
  • 23 Matarese G. Leptin and the immune system: how nutritional status influences the immune response.  Eur Cytokine Netw. 2000;  11 7-14
    PubMedGoogle Scholar
  • 24 Friedman J M, Halaas J L. Leptin and the regulation of body weight in mammals.  Nature. 1998;  395 763-770
    CrossrefPubMedGoogle Scholar
  • 25 Pelleymounter M A, Cullen M J, Baker M B, Hecht R, Winters D, Boone T, Collins F. Effects of the obese gene product on body weight regulation in ob/ob mice.  Science. 1995;  269 540-543
    CrossrefPubMedGoogle Scholar
  • 26 Heiman M L, Ahima R S, Craft L S, Schoner B, Stephens T W, Flier J S. Leptin inhibition of the hypothalamic-pituitary-adrenal axis in response to stress.  Endocrinology. 1997;  138 3859-3863
    CrossrefPubMedGoogle Scholar
  • 27 Chehab F F, Mounzih K, Lu R, Lim M E. Early onset of reproductive function in normal female mice treated with leptin.  Science. 1997;  275 88-90
    CrossrefPubMedGoogle Scholar
  • 28 Ong K K, Ahmed M L, Dunger D B. The role of leptin in human growth and puberty.  Acta Paediatr. 1999;  88 Suppl 95-98
    CrossrefPubMedGoogle Scholar
  • 29 Blum W F. Leptin: the voice of the adipose tissue.  Horm Res. 1997;  48 Suppl 4 2-8
    PubMedGoogle Scholar
  • 30 Ahima R S, Bjorbaek C, Osei S, Flier J S. Regulation of neuronal and glial proteins by leptin: implications for brain development.  Endocrinology. 1999;  140 2755-2762
    CrossrefPubMedGoogle Scholar
  • 31 Beutler B, Mahoney J, Le Trang N, Pekala P, Cerami A. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells.  J Exp Med. 1985;  161 984-995
    CrossrefPubMedGoogle Scholar
  • 32 Beutler B, Greenwald D, Hulmes J D, Chang M, Pan Y C, Mathison J, Ulevitch R, Cerami A. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin.  Nature. 1985;  316 552-554
    CrossrefPubMedGoogle Scholar
  • 33 Hinze-Selch D, Schuld A, Kraus T, Kühn M, Uhr M, Haack M, Pollmächer T. Effects of antidepressants on weight and on the plasma levels of leptin, TNF- and soluble TNF receptors: a longitudinal study in patients treated with amitriptyline or paroxetine.  Neuropsychopharmacol. 2000;  23 13-19
    CrossrefPubMedGoogle Scholar
  • 34 Schuld A, Kraus T, Haack M, Hinze-Selch D, Kühn M, Pollmächer T. Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine.  Schizophr Res. 2000;  102 1-3
    PubMedGoogle Scholar
  • 35 Müller-Oerlinghausen B, Passoth P M, Poser W, Schlecht W. Zum Einfluss langfristiger Behandlung mit Neuroleptika oder Lithiumsalzen auf den Kohlehydratstoffwechsel.  Arzneimittelforschung. 1978;  28 1522-1524
    PubMedGoogle Scholar
  • 36 Fuchs G, Böning J. Appetenzwandel und Gewichtsänderung.  MMW. 1985;  127 43-46
    PubMedGoogle Scholar
  • 37 Fernstrom M H. Drugs that cause weight gain.  Obes Res. 1995;  3 Suppl 4 435-439
    PubMedGoogle Scholar
  • 38 Cantu T G, Korek J S. Monamine oxidase inhibitors and weight gain.  Drug Intell Clin Pharm. 1988;  22 755-759
    PubMedGoogle Scholar
  • 39 Baptista T, Teneud L, Contreras Q, Alastre T, Burguera J L, de Burguera M, de Baptista E, Weiss S, Hernandez L. Lithium and body weight gain.  Pharmacopsychiatry. 1995;  28 35-44
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Stanton J M. Weight gain associated with neuroleptic medication: a review.  Schizophr Bull. 1995;  21 463-472
    PubMedGoogle Scholar
  • 41 Wirshing D A, Wirshing W C, Kysar L, Berisford M A, Goldstein D, Pashdag J, Mintz J, Marder S R. Novel antipsychotics: comparison of weight gain liabilities.  J Clin Psychiatry. 1999;  60 358-363
    CrossrefPubMedGoogle Scholar
  • 42 Goldstein D J, Rampey Jr A H, Enas G G, Potvin J H, Fludzinski L A, Levine L R. Fluoxetine: a randomized clinical trial in the treatment of obesity.  Int J Obes Relat Metab Disord. 1994;  18 129-135
    PubMedGoogle Scholar
  • 43 Lawton C L, Wales J K, Hill A J, Blundell J E. Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects.  Obes Res. 1995;  3 345-356
    PubMedGoogle Scholar
  • 44 Michelson D, Amsterdam J D, Quitkin F M, Reimherr F W, Rosenbaum J F, Zajecka J, Sundell K L, Kim Y, Beasley C MJ. Changes in weight during a 1-year trial of fluoxetine.  Am J Psychiatry. 1999;  156 1170-1176
    PubMedGoogle Scholar
  • 45 Ward A S, Comer S D, Haney M, Fischman M W, Foltin R W. Fluoxetine-maintained obese humans: effect on food intake and body weight.  Physiol Behav. 1999;  66 815-821
    CrossrefPubMedGoogle Scholar
  • 46 Bagnall A, Fenton M, Lewis R, Leitner M L, Kleijnen J. Molindone for schizophrenia and severe mental illness.  Cochrane Database Syst Rev. 2000;  2 CD002083
    PubMedGoogle Scholar
  • 47 Gardos G, Cole J O. Weight reduction in schizophrenics by molindone.  Am J Psychiatry. 1977;  134 302-304
    PubMedGoogle Scholar
  • 48 Heikkinen H, Outakoski J, Merilainen V, Tuomi A, Huttunen M O. Molindone and weight loss.  J Clin Psychiatry. 1993;  54 160-161
    PubMedGoogle Scholar
  • 49 Ben-Menachem E, Henriksen O, Dam M, Mikkelsen M, Schmidt D, Reid S, Reife R, Kramer L, Pledger G, Karim R. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures.  Epilepsia. 1996;  37 539-543
    PubMedGoogle Scholar
  • 50 Dursun S M, Devarajan S. Clozapine weight gain, plus topiramate weight loss.  Can J Psychiatry. 2000;  45 198
    PubMedGoogle Scholar
  • 51 Shorvon S D. Safety of topiramate: adverse events and relationships to dosing.  Epilepsia. 1996;  37 Suppl 2 18-22
    PubMedGoogle Scholar
  • 52 Bergen D C, Ristanovic R K, Waicosky K, Kanner A, Hoeppner T J. Weight loss in patients taking felbamate.  Clin Neuropharmacol. 1995;  18 23-27
    PubMedGoogle Scholar
  • 53 Carmant L, Holmes G L, Sawyer S, Rifai N, Anderson J, Mikati M A. Efficacy of felbamate in therapy for partial epilepsy in children.  J Pediatr. 1994;  125 481-486
    CrossrefPubMedGoogle Scholar
  • 54 Balon R, Yeragani V K, Pohl R, Merlos B, Sherwood P. Changes in appetite and weight during the pharmacological treatment of patients with panic disorder.  Can J Psychiatry. 1993;  38 19-22
    PubMedGoogle Scholar
  • 55 Fava M. Weight gain during short-term and long-term treatment with antidepressants.  Primary Psychiatry. 2000;  7 28-32
    PubMedGoogle Scholar
  • 56 Barak Y, Lampl Y, Achiron A, Sarova-Pinhas I, Elizur A. Fluoxetine induced weight loss: a pilot study in postpartum women.  Isr J Psychiatry Relat Sci. 1995;  32 51-54
    PubMedGoogle Scholar
  • 57 Benjamin E, Bout Smith T. Naltrexone and fluoxetine in Prader-Willi syndrome.  J Am Acad Child Adolesc Psychiatry. 1993;  32 870-3IS
    PubMedGoogle Scholar
  • 58 Borrelli B, Spring B, Niaura R, Kristeller J, Ockene J K, Keuthen N J. Weight suppression and weight rebound in ex-smokers treated with fluoxetine.  J Consult Clin Psychol. 1999;  67 124-131
    CrossrefPubMedGoogle Scholar
  • 59 Fernandez-Soto M L, Gonzalez-Jimenez A, Barredo-Acedo F, Luna dC JD, Escobar-Jimenez F. Comparison of fluoxetine and placebo in the treatment of obesity.  Ann Nutr Metab. 1995;  39 159-163
    PubMedGoogle Scholar
  • 60 Fichtner C G, Braun B G. Hyperphagia and weight loss during fluoxetine treatment.  Ann Pharmacother. 1994;  28 1350-1352
    PubMedGoogle Scholar
  • 61 Goldstein D J, Rampey A HJ, Roback P J, Wilson M G, Hamilton S H, Sayler M E, Tollefson G D. Efficacy and safety of long-term fluoxetine treatment of obesity - maximizing success.  Obes Res. 1995;  3 Suppl 4 481-490
    PubMedGoogle Scholar
  • 62 Gray D S, Fujioka K, Devine W, Bray G A. Fluoxetine treatment of the obese diabetic.  Int J Obes Relat Metab Disord. 1992;  16 193-198
    PubMedGoogle Scholar
  • 63 Kutnowski M, Daubresse J C, Friedman H, Kolanowski J, Krzentowski G, Scheen A, Van Gaal L. Fluoxetine therapy in obese diabetic and glucose intolerant patients.  Int J Obes Relat Metab Disord. 1992;  16 Suppl 4 63-66
    PubMedGoogle Scholar
  • 64 McGuirk J, Silverstone T. The effect of the 5-HT re-uptake inhibitor fluoxetine on food intake and body weight in healthy male subjects.  Int J Obes. 1990;  14 361-372
    PubMedGoogle Scholar
  • 65 Sayler M E, Goldstein D J, Roback P J, Atkinson R L. Evaluating success of weight loss programs, with an application to fluoxetine weight reduction clinical trial data.  Int J Obes Relat Metab Disord. 1994;  18 742-751
    PubMedGoogle Scholar
  • 66 Spring B, Wurtman J, Wurtman R, el-Khoury A, Goldberg H, McDermott J, Pingitore R. Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation.  Am J Clin Nutr. 1995;  62 1181-1187
    PubMedGoogle Scholar
  • 67 Visser M, Seidell J C, Koppeschaar H P, Smits P. The effect of fluoxetine on body weight, body composition and visceral fat accumulation.  Int J Obes Relat Metab Disord. 1993;  17 247-253
    PubMedGoogle Scholar
  • 68 Wurtman J, Wurtman R, Berry E, Gleason R, Goldberg H, McDermott J, Kahne M, Tsay R. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers.  Neuropsychopharmacol. 1993;  9 201-210
    PubMedGoogle Scholar
  • 69 Wadden T A, Bartlett S J, Foster G D, Greenstein R A, Wingate B J, Stunkard A J, Letizia K A. Sertraline and relapse prevention training following treatment by very-low-calorie diet: a controlled clinical trial.  Obes Res. 1995;  3 549-557
    PubMedGoogle Scholar
  • 70 Laakmann G, Blaschke D, Engel R, Schwarz A. Fluoxetine vs. amitriptyline in the treatment of depressed out-patients.  Br J Psychiatry. 1988;  Suppl 64-68
    PubMedGoogle Scholar
  • 71 Szarek B L, Brandt D M. A comparison of weight changes with fluoxetine, desipramine, and amitriptyline: a retrospective study of psychiatric inpatients.  J Nerv Ment Dis. 1993;  181 702-704
    PubMedGoogle Scholar
  • 72 Finkel S I, Richter E M, Clary C M, Batzar E. Comparative efficacy of sertraline vs. fluoxetine in patients age 70 or over with major depression.  Am J Geriatr Psychiatry. 1999;  7 221-227
    PubMedGoogle Scholar
  • 73 Fava M. Weight gain and antidepressants.  J Clin Psychiatry. 2000;  61 Suppl 11 37-41
    PubMedGoogle Scholar
  • 74 Weber E, Stack J, Pollock B G, Mussant B, Begley A, Mazumdar S, Reynolds I II. Weight change in older depressed patients during acute pharmacotherapy with paroxetine and nortriptyline: A double-blind randomized trial.  Am J Geriatr Psychiatry. 2000;  8 245-250
    PubMedGoogle Scholar
  • 75 Chouinard G, Saxena B, Belanger M C, Ravindran A, Bakish D, Beauclair L, Morris P, Vasavan N N, Manchanda R, Reesal R, Remick R, O'Neill M C. A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder.  J Affect Disord. 1999;  54 39-48
    CrossrefPubMedGoogle Scholar
  • 76 Wurtman J J. Depression and weight gain: the serotonin connection.  J Affect Disord. 1993;  29 183-192
    CrossrefPubMedGoogle Scholar
  • 77 Chambers C D, Anderson P O, Thomas R G, Dick L M, Felix R J, Johnson K A, Jones K L. Weight gain in infants breastfed by mothers who take fluoxetine.  Pediatrics. 1999;  104 e61
    CrossrefPubMedGoogle Scholar
  • 78 de Zwaan M, Nutzinger D O. Effect of fluvoxamine on total serum cholesterol levels during weight reduction.  J Clin Psychiatry. 1996;  57 346-348
    PubMedGoogle Scholar
  • 79 Szkudlarek J, Elsborg L. Treatment of severe obesity with a highly selective serotonin re-uptake inhibitor as a supplement to a low calorie diet.  Int J Obes Relat Metab Disord. 1993;  17 681-683
    PubMedGoogle Scholar
  • 80 Walsh B T, Devlin M J. Pharmacotherapy of bulimia nervosa and binge eating disorder.  Addict Behav. 1995;  20 757-764
    CrossrefPubMedGoogle Scholar
  • 81 Horst W D, Preskorn S H. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion.  J Affect Disord. 1998;  51 237-254
    CrossrefPubMedGoogle Scholar
  • 82 Robinson D S, Roberts D L, Smith J M, Stringfellow J C, Kaplita S B, Seminara J A, Marcus R N. The safety profile of nefazodone.  J Clin Psychiatry. 1996;  57 Suppl 2 31-38
    PubMedGoogle Scholar
  • 83 Settle Jr E C. Bupropion sustained release: side effect profile.  J Clin Psychiatry. 1998;  59 Suppl 4 32-36
    PubMedGoogle Scholar
  • 84 Workman E A, Short D D. Bupropion-induced carbohydrate craving and weight gain.  Am J Psychiatry. 1992;  149 1407-1408
    PubMedGoogle Scholar
  • 85 Holm K J, Spencer C M. Bupropion: a review of its use in the management of smoking cessation.  Drugs. 2000;  59 1007-1024
    PubMedGoogle Scholar
  • 86 Burrows G D, Kremer C M. Mirtazapine: clinical advantages in the treatment of depression.  J Clin Psychopharmacol. 1997;  17 Suppl 34-39
    CrossrefPubMedGoogle Scholar
  • 87 Davis R, Wilde M I. Mirtazapine. A review of its pharmacology and therapeutic potential in the management of major depression.  CNS Drugs. 1996;  5 389-402
    PubMedGoogle Scholar
  • 88 Carpenter L L, Jocic Z, Hall J M, Rasmussen S A, Price L H. Mirtazapine augmentation in the treatment of refractory depression.  J Clin Psychiatry. 1999;  60 45-49
    PubMedGoogle Scholar
  • 89 Schou M, Baastrup P C, Grof P, Weiss P, Angst P J. Pharmacological and clinical problems of lithium prophylaxis.  Br J Psychiatry. 1970;  116 615-619
    PubMedGoogle Scholar
  • 90 Vendsborg P B, Bech P, Rafaelsen O J. Lithium treatment and weight gain.  Acta Psychiatr Scand. 1976;  53 139-147
    PubMedGoogle Scholar
  • 91 Peselow E D, Dunner D L, Fieve R R, Lautin A. Lithium carbonate and weight gain.  J Affect Disord. 1980;  2 303-310
    CrossrefPubMedGoogle Scholar
  • 92 Müller-Oerlinghausen B, Passoth P M, Poser W, Pudel V. Impaired glucose tolerance in long-term lithium treated patients.  Int Pharmacopsychiat. 1979;  14 350-362
    PubMedGoogle Scholar
  • 93 Vestergaard P, Poulstrup I, Schou M. Prospective studies on a lithium cohort 3: Tremor, weight gain, diarrhea, psychological complaints.  Acta Psychiatr Scand. 1988;  78 434-441
    PubMedGoogle Scholar
  • 94 Kerry R J, Liebling L I, Owen G. Weight changes in lithium responders.  Acta Psychiatr Scand. 1970;  46 238-243
    PubMedGoogle Scholar
  • 95 Davis L L, Ryan W, Adinoff B, Petty F. Comprehensive review of the psychiatric uses of valproate.  J Clin Psychopharmacol. 2000;  20 1-17
    CrossrefPubMedGoogle Scholar
  • 96 Retzow A, Emrich H M. Therapie bipolarer affektiver Erkrankungen mit Valproat. Eine Literaturübersicht.  Psychiatrische Praxis. 1998;  25 163-171
    PubMedGoogle Scholar
  • 97 Davis J M, Janicak P G, Hogan D M. Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis.  Acta Psychiatr Scand. 1999;  100 406-417
    PubMedGoogle Scholar
  • 98 Walden J, Normann C, Langosch J, Grunze H. Wirksamkeitspradiktoren für Phasenprophylaktika (Stimmungsstabilisierer) bei bipolaren affektiven Störungen.  Fortschr Neurol Psychiat. 1999;  67 75-80
    PubMedGoogle Scholar
  • 99 Cabrera J, Albrecht J, Müller-Oerlinghausen B. Kombinierte rezidiv-prophylaktische Behandlung der manisch-depressiven Erkrankung mit Lithium und Carbamazepin oder Oxcarbazepin.  Nervenarzt. 1987;  58 245-249
    PubMedGoogle Scholar
  • 100 Post R M, Frye M A, Denicoff K D, Leverich G S, Kimbrell T A, Dunn R T. Beyond lithium in the treatment of bipolar illness.  Neuropsychopharmacol. 1998;  19 206-219
    PubMedGoogle Scholar
  • 101 Emrich H M, Wolf R. Valproate treatment of mania.  Prog Neuropsychopharmacol Biol Psychiatry. 1992;  16 691-701
    CrossrefPubMedGoogle Scholar
  • 102 Jacobsen F M. Low-dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome.  J Clin Psychiatry. 1993;  54 229-234
    PubMedGoogle Scholar
  • 103 Bowden C L. New concepts in mood stabilization: evidence for the effectiveness of valproate and lamotrigine.  Neuropsychopharmacol. 1998;  19 194-199
    PubMedGoogle Scholar
  • 104 Dietrich D E, Emrich H M. The use of anticonvulsants to augment antidepressant medication.  J Clin Psychiatry. 1998;  59 Suppl 5 51-58
    PubMedGoogle Scholar
  • 105 Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabilizer.  J Affect Disord. 1998;  50 245-251
    CrossrefPubMedGoogle Scholar
  • 106 Gordon A, Price L H. Mood stabilization and weight loss with topiramate.  Am J Psychiatry. 1999;  156 968-969
    PubMedGoogle Scholar
  • 107 Ketter T A, Post R M, Theodore W H. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders.  Neurology. 1999;  53 Suppl 2 53-67
    PubMedGoogle Scholar
  • 108 Isojarvi J I, Laatikainen T J, Knip M, Pakarinen A J, Juntunen K T, Myllyla V V. Obesity and endocrine disorders in women taking valproate for epilepsy.  Ann Neurol. 1996;  39 579-584
    CrossrefPubMedGoogle Scholar
  • 109 Novak G P, Maytal J, Alshansky A, Eviatar L, Sy-Kho R, Siddique Q. Risk of excessive weight gain in epileptic children treated with valproate.  J Child Neurol. 1999;  14 490-495
    PubMedGoogle Scholar
  • 110 Easter D, O'Bryan-Tear C G, Verity C. Weight gain with valproate or carbamazepine - a reappraisal.  Seizure. 1997;  6 121-125
    CrossrefPubMedGoogle Scholar
  • 111 Calabrese J, Goethe J W, Kayser A, Marcotte D B, Monagin J A, Kimmel S E, Brugger A M, Morris D, Fatemi S H. Adverse events in 583 valproate-treated patients.  Depression. 1996;  3 257-262
    PubMedGoogle Scholar
  • 112 Allison D B, Mentore J L, Heo M, Chandler L P, Cappelleri J C, Infante M C, Weiden P J. Antipsychotic-induced weight gain: a comprehensive research synthesis.  Am J Psychiatry. 1999;  156 1686-1696
    PubMedGoogle Scholar
  • 113 Silverstone T, Smith G, Goodall E. Prevalence of obesity in patients receiving depot antipsychotics.  Br J Psychiatry. 1988;  153 214-217
    PubMedGoogle Scholar
  • 114 Stedman T, Welham J. The distribution of adipose tissue in female in-patients receiving psychotropic drugs.  Br J Psychiatry. 1993;  162 249-250
    PubMedGoogle Scholar
  • 115 Escobar J I, Mann J J, Keller J, Wilkins J, Mason B, Mills M J. Comparison of injectible molindone and haloperidol followed by oral dosage forms in acutely ill schizophrenics.  J Clin Psychiatry. 1985;  46 15-19
    PubMedGoogle Scholar
  • 116 Owen R R, Cole J O. Molindone hydrochloride: A review of laboratory and clinical findings.  J Clin Psychopharmacol. 1989;  9 268-276
    PubMedGoogle Scholar
  • 117 Claghorn J L. Review of clinical and laboratory experiences with molindone hydrochloride.  J Clin Psychiatry. 1985;  46 30-33
    PubMedGoogle Scholar
  • 118 Glazer W M, Hafez H M, Benarroche C L. Molindone and haloperidol in tardive dyskinesia.  J Clin Psychiatry. 1985;  46 4-7
    PubMedGoogle Scholar
  • 119 McCready R, Mackie M, Morrison D, Kidd J. Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia.  Br J Psychiatry. 1982;  140 280-286
    PubMedGoogle Scholar
  • 120 Falloon I, Watt D C, Shepherd M. A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia.  Psychol Med. 1978;  8 59-70
    PubMedGoogle Scholar
  • 121 Wetterling T, Mussigbrodt H E. Weight gain: side effect of atypical neuroleptics?.  J Clin Psychopharmacol. 1999;  19 316-321
    CrossrefPubMedGoogle Scholar
  • 122 Schmidt L G. Utilization and safety of fluspirilene in nonpsychotic outpatients.  Pharmacopsychiatry. 1989;  22 188-191
    PubMedGoogle Scholar
  • 123 Kelly D L, Conley R R, Love R C, Horn D S, Ushchak C M. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months.  J Child Adolesc Psychopharmacol. 1998;  8 151-159
    PubMedGoogle Scholar
  • 124 Frankenburg F R, Zanarini M C, Kando J, Centorrino F. Clozapine and body mass change.  Biol Psychiatry. 1998;  43 520-524
    CrossrefPubMedGoogle Scholar
  • 125 Gunasekara N S, Spencer C M. Quetiapine. A review of its use in schizophrenia.  CNS Drugs. 1998;  9 325-340
    PubMedGoogle Scholar
  • 126 Peuskens J, Link C G. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia.  Acta Psychiatr Scand. 1997;  96 265-273
    PubMedGoogle Scholar
  • 127 Arvantis L A, Miller B G. , Seroquel Trial 13 Study Group . Multiple fixed doses of “Seroquel” (Quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo.  Biol Psychiatry. 1997;  42 233-246
    CrossrefPubMedGoogle Scholar
  • 128 Stunkard A J, Fernstrom M H, Price A, Frank E, Kupfer D J. Direction of weight change in recurrent depression.  Arch Gen Psychiatry. 1990;  47 857-860
    PubMedGoogle Scholar
  • 129 Fernstrom M H, Kupfer D J. Imipramine Treatment and Preference for Sweets.  Appetite. 1988;  10 149-155
    CrossrefPubMedGoogle Scholar
  • 130 Kazes M, Danion J M, Grange D, Pradignac A, Simon C, Burrus Mehl F, Schlienger J L, Singer L. Eating behaviour and depression before and after antidepressant treatment: a prospective, naturalistic study.  J Affect Disord. 1994;  30 193-207
    CrossrefPubMedGoogle Scholar
  • 131 Baptista T, Mata A, Teneud L, de Quijada M, Han H W, Hernandez L. Effects of long-term administration of clozapine on body weight and food intake in rats.  Pharmacol Biochem Behav. 1993;  45 51-54
    CrossrefPubMedGoogle Scholar
  • 132 Storlien L H, Higson F M, Gleeson R M, Smythe G A, Atrens D M. Effects of Chronic Lithium, Amitriptyline and Mianserin on Glucoregulation, Corticosterone and Energy Balance in the Rat.  Pharmacol Biochem Behav. 1985;  22 119-125
    CrossrefPubMedGoogle Scholar
  • 133 Paykel E S, Mueller P S, De l V. Amitriptyline, weight gain and carbohydrate craving: a side effect.  Br J Psychiatry. 1973;  123 501-507
    PubMedGoogle Scholar
  • 134 Pijl H, Koppeschaar H P, Cohen A F, Iestra J A, Schoemaker H C, Frolich M, Onkenhout W, Meinders A E. Evidence for brain serotonin-mediated control of carbohydrate consumption in normal weight and obese humans.  Int J Obes Relat Metab Disord. 1993;  17 513-520
    PubMedGoogle Scholar
  • 135 Stunkard A J, Messick S. The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger.  J Psychosom Res. 1985;  29 71-83
    CrossrefPubMedGoogle Scholar
  • 136 Pudel V, Westenhöfer J. Fragebogen zum Essverhalten (FEV). Göttingen: Verlag für Psychologie Dr. C. J. Hogrefe 1989
    Google Scholar
  • 137 Fernstrom M H, Epstein L H, Spiker D G, Kupfer D J. Resting metabolic rate is reduced in patients treated with antidepressants.  Biol Psychiatry. 1985;  20 692-695
    CrossrefPubMedGoogle Scholar
  • 138 Weiss H. Ueber eine neue Behandlungsmethode des Diabetes Mellitus und verwandter Stoffwechselstörungen.  Wien Klin Wochenschr. 1924;  37 1142
    PubMedGoogle Scholar
  • 139 Vendsborg P B, Rafaelsen O J. Lithium in Man: Effect on Glucose Tolerance and Serum Electrolytes.  Acta Psychiatr Scand. 1973;  49 601-610
    PubMedGoogle Scholar
  • 140 Jones G R, Lazarus J H, Davies C J, Greenwood R H. The effect of short term lithium carbonate in Type II diabetes mellitus.  Horm Metab Res. 1983;  15 422-424
    PubMedGoogle Scholar
  • 141 Fontela T, Hermida O G, Gomez-Acebo J. Blocking Effect of Naloxone, Dihydroergotamine and Adrenalectomy in Lithium-Induced Hyperglycemia and Glucose Intolerance in the Rat.  Acta Endocrinol Copenh. 1986;  111 342-348
    PubMedGoogle Scholar
  • 142 Shopsin B, Stern S, Gershon S. Altered Carbohydrate Metabolism During Treatment with Lithium Carbonate.  Arch Gen Psychiatry. 1972;  26 566-571
    PubMedGoogle Scholar
  • 143 Maheux P, Ducros F, Bourque J, Garon J, Chiasson J L. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss.  Int J Obes Relat Metab Disord. 1997;  21 97-102
    CrossrefPubMedGoogle Scholar
  • 144 Popli A P, Konicki P E, Jurjus G J, Fuller M A, Jaskiw G E. Clozapine and associated diabetes mellitus.  J Clin Psychiatry. 1997;  58 108-111
    PubMedGoogle Scholar
  • 145 Wirshing D A, Spellberg B J, Erhart S M, Marder S R, Wirshing W C. Novel antipsychotics and new onset diabetes.  Biol Psychiatry. 1998;  44 778-783
    CrossrefPubMedGoogle Scholar
  • 146 Uvnas-Moberg K, Ahlenius S, Alster P, Hillegaart V. Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin and glucagon in the rat.  Neuroendocrinology. 1996;  63 269-274
    PubMedGoogle Scholar
  • 147 Cseh K, Winkler G, Melczer Z, Baranyi E. The role of tumour necrosis factor (TNF-)alpha resistance in obesity and insulin resistance.  Diabetologia. 2000;  43 525
    CrossrefPubMedGoogle Scholar
  • 148 Hube F, Hauner H. The role of TNF-alpha in human adipose tissue: prevention of weight gain at the expense of insulin resistance?.  Horm Metab Res. 1999;  31 626-631
    Article in Thieme ConnectPubMedGoogle Scholar
  • 149 Qi C, Pekala P H. Tumor necrosis factor-alpha-induced insulin resistance in adipocytes.  Proc Soc Exp Biol Med. 2000;  223 128-135
    CrossrefPubMedGoogle Scholar
  • 150 Corica F, Allegra A, Corsonello A, Buemi M, Calapai G, Ruello A, Nicita M V, Ceruso D. Relationship between plasma leptin levels and the tumor necrosis factor-alpha system in obese subjects.  Int J Obes Relat Metab Disord. 1999;  23 355-360
    CrossrefPubMedGoogle Scholar
  • 151 Hotamisligil G S. The role of TNFalpha and TNF receptors in obesity and insulin resistance.  J Intern Med. 1999;  245 621-625
    CrossrefPubMedGoogle Scholar
  • 152 Pollmächer T, Hinze-Selch D, Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels.  J Clin Psychopharmacol. 1996;  16 403-409
    CrossrefPubMedGoogle Scholar
  • 153 Goldstein L E, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey G K, Sachs G, Stern T A. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment.  Psychosomatics. 1999;  40 438-443
    PubMedGoogle Scholar
  • 154 Ober S K, Hudak R, Rusterholtz A. Hyperglycemia and olanzapine.  Am J Psychiatry. 1999;  156 970
    PubMedGoogle Scholar
  • 155 Fertig M K, Brooks V G, Shelton P S, English C W. Hyperglycemia associated with olanzapine.  J Clin Psychiatry. 1998;  59 687-689
    PubMedGoogle Scholar
  • 156 Schwartz M W, Woods S C, Porte D J, Seeley R J, Baskin D G. Central nervous system control of food intake.  Nature. 2000;  404 661-671
    CrossrefPubMedGoogle Scholar
  • 157 Kalra S P, Dube M G, Pu S, Xu B, Horvath T L, Kalra P S. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight.  Endocr Rev. 1999;  20 68-100
    CrossrefPubMedGoogle Scholar
  • 158 Cooper S J, Clifton P G. Drug receptor subtypes and ingestive behaviour. London: Acedemic Press 1996
    Google Scholar
  • 159 Tecott L H, Sun L M, Akana S F, Strack A M, Lowenstein D H, Dallman M F, Julius D. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors.  Nature. 1995;  374 542-546
    CrossrefPubMedGoogle Scholar
  • 160 Meltzer H Y, Nash J F. Effects of antipsychotic drugs on serotonin receptors.  Pharmacol Rev. 1991;  43 587-604
    PubMedGoogle Scholar
  • 161 Meltzer H Y, Matsubara S, Lee J C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.  J Pharmacol Exp Ther. 1989;  251 238-246
    PubMedGoogle Scholar
  • 162 Moore N A. Behavioural pharmacology of the new generation of antipsychotic agents.  Br J Psychiatry. 1999;  38 Suppl 5-11
    PubMedGoogle Scholar
  • 163 Currie P J. Medial hypothalamic alpha-2-adrenergic and serotonergic effects on ingestive behaviour. In: Cooper SJ, Clifton PG (Hrsg). Drug receptor subtypes and ingestive behaviour London: Academic Press 1996: 285-300
    Google Scholar
  • 164 Terry P. Dopamine receptor subtypes and ingestive behaviour. In: Cooper SJ, Clifton PG (Hrsg). Drug receptor subtypes and ingestive behaviour London: Academic Press 1996: 233-266
    Google Scholar
  • 165 Lecklin A, Etu-Seppala P, Stark H, Tuomisto L. Effects of intracerebroventricularly infused histamine and selective H1, H2 and H3 agonists on food and water intake and urine flow in Wistar rats.  Brain Res. 1998;  793 279-288
    CrossrefPubMedGoogle Scholar
  • 166 Mercer L P. Histamine and the neuroregulation of food intake.  Nutrition. 1997;  13 581-582
    CrossrefPubMedGoogle Scholar
  • 167 Mann K V, Crowe J P, Tietze K J. Nonsedating histamine H1-receptor antagonists.  Clin Pharm. 1989;  8 331-344
    PubMedGoogle Scholar
  • 168 Krstenansky P M, Cluxton R JJ. Astemizole: a long-acting, nonsedating antihistamine.  Drug Intell Clin Pharm. 1987;  21 947-953
    PubMedGoogle Scholar
  • 169 Wilson J D, Hillas J L. Astemizole: a new long-acting antihistamine in the treatment of seasonal allergic rhinitis.  Clin Allergy. 1983;  13 131-140
    PubMedGoogle Scholar
  • 170 Hervey G R. Regulation of energy balance.  Nature. 1969;  222 629-631
    PubMedGoogle Scholar
  • 171 Edholm O G. Energy balance in man studies carried out by the Division of Human Physiology, National Institute for Medical Research.  J Hum Nutr. 1977;  31 413-431
    PubMedGoogle Scholar
  • 172 Kennedy G C. The role of depot fat in the hypothalamic control of food intake in the rat.  Proc R Soc Lond B. 1953;  140 579-592
    PubMedGoogle Scholar
  • 173 Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman J M. Positional cloning of the mouse obese gene and its human homologue.  Nature. 1994;  372 425-432
    CrossrefPubMedGoogle Scholar
  • 174 Friedman J M. Leptin, leptin receptors and the control of body weight.  Eur J Med Res. 1997;  2 7-13
    PubMedGoogle Scholar
  • 175 Stellar E. The physiology of motivation.  Psychol Rev. 1994;  101 301-311
    PubMedGoogle Scholar
  • 176 Dallman M F, Strack A M, Akana S F, Bradbury M J, Hanson E S, Scribner K A, Smith M. Feast and famine: critical role of glucocorticoids with insulin in daily energy flow.  Front Neuroendocrinol. 1993;  14 303-347
    CrossrefPubMedGoogle Scholar
  • 177 Kow L M, Pfaff D W. The effects of the TRH metabolite cyclo(His-Pro) and its analogs on feeding.  Pharmacol Biochem Behav. 1991;  38 359-364
    CrossrefPubMedGoogle Scholar
  • 178 Verbalis J G, Blackburn R E, Hoffman G E, Stricker E M. Establishing behavioral and physiological functions of central oxytocin: insights from studies of oxytocin and ingestive behaviors.  Adv Exp Med Biol. 1995;  395 209-225
    PubMedGoogle Scholar
  • 179 Qu D, Ludwig D S, Gammeltoft S, Piper M, Pelleymounter M A, Cullen M J, Mathes W F, Przypek R, Kanarek R, Maratos-Flier E. A role for melanin-concentrating hormone in the central regulation of feeding behaviour.  Nature. 1996;  380 243-247
    CrossrefPubMedGoogle Scholar
  • 180 Shimada M, Tritos N A, Lowell B B, Flier J S, Maratos-Flier E. Mice lacking melanin-concentrating hormone are hypophagic and lean.  Nature. 1998;  396 670-674
    CrossrefPubMedGoogle Scholar
  • 181 Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli R M, Tanaka H, Williams S C, Richardson J A, Kozlowski G P, Wilson S, Arch J R, Buckingham R E, Haynes A C, Carr S A, Annan R S, McNulty D E, Liu W S, Terrett J A, Elshourbagy N A, Bergsma D J, Yanagisawa M. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.  Cell. 1998;  92 573-585
    CrossrefPubMedGoogle Scholar
  • 182 Weigle D S, Duell P B, Connor W E, Steiner R A, Soules M R, Kuijper J L. Effect of fasting, refeeding, and dietary fat restriction on plasma leptin levels.  J Clin Endocrinol Metab. 1997;  82 561-565
    CrossrefPubMedGoogle Scholar
  • 183 Auwerx J, Staels B. Leptin.  Lancet. 1998;  351 737-742
    CrossrefPubMedGoogle Scholar
  • 184 Montague C T, Farooqi I S, Whitehead J P, Soos M A, Rau H, Wareham N J, Sewter C P, Digby J E, Mohammed S N, Hurst J A, Cheetham C H, Early A R, Barnett A H, Prins J B, O'Rahilly S. Congenital leptin deficiency is associated with severe early-onset obesity in humans.  Nature. 1997;  387 903-908
    CrossrefPubMedGoogle Scholar
  • 185 Farooqi I S, Jebb S A, Langmack G, Lawrence E, Cheetham C H, Prentice A M, Hughes I A, McCamish M A, O'Rahilly S. Effects of recombinant leptin therapy in a child with congenital leptin deficiency.  N Engl J Med. 1999;  341 879-884
    CrossrefPubMedGoogle Scholar
  • 186 Kolaczynski J W, Ohannesian J P, Considine R V, Marco C C, Caro J F. Response of leptin to short-term and prolonged overfeeding in humans.  J Clin Endocrinol Metab. 1996;  81 4162-4165
    CrossrefPubMedGoogle Scholar
  • 187 Burguera B, Couce M E, Curran G L, Jensen M D, Lloyd R V, Cleary M P, Poduslo J F. Obesity is associated with a decreased leptin transport across the blood-brain barrier in rats.  Diabetes. 2000;  49 1219-1223
    CrossrefPubMedGoogle Scholar
  • 188 Koistinen H A, Karonen S L, Iivanainen M, Koivisto V A. Circulating leptin has saturable transport into intrathecal space in humans.  Eur J Clin Invest. 1998;  28 894-897
    CrossrefPubMedGoogle Scholar
  • 189 Schwartz M W, Peskind E, Raskind M, Boyko E J, Porte D J. Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans.  Nat Med. 1996;  2 589-593
    PubMedGoogle Scholar
  • 190 McGregor G P, Desaga J F, Ehlenz K, Fischer A, Heese F, Hegele A, Lammer C, Peiser C, Lang R E. Radioimmunological measurement of leptin in plasma of obese and diabetic human subjects.  Endocrinology. 1996;  137 1501-1504
    CrossrefPubMedGoogle Scholar
  • 191 Maffei M, Halaas J, Ravussin E, Pratley R E, Lee G H, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects.  Nat Med. 1995;  1 1155-1161
    CrossrefPubMedGoogle Scholar
  • 192 Ma Z, Gingerich R L, Santiago J V, Klein S, Smith C H, Landt M. Radioimmunoassay of leptin in human plasma.  Clin Chem. 1996;  42 942-946
    PubMedGoogle Scholar
  • 193 Rosenbaum M, Nicolson M, Hirsch J, Heymsfield S B, Gallagher D, Chu F, Leibel R L. Effects of gender, body composition, and menopause on plasma concentrations of leptin.  J Clin Endocrinol Metab. 1996;  81 3424-3427
    CrossrefPubMedGoogle Scholar
  • 194 Friedman J M. Obesity in the new millennium.  Nature. 2000;  404 632-634
    PubMedGoogle Scholar
  • 195 Leibowitz S F, Roossin P, Rosenn M. Chronic norepinephrine injection into the hypothalamic paraventricular nucleus produces hyperphagia and increased body weight in the rat.  Pharmacol Biochem Behav. 1984;  21 801-808
    PubMedGoogle Scholar
  • 196 Oltmans G A. Norepinephrine and dopamine levels in hypothalamic nuclei of the genetically obese mouse (ob/ob).  Brain Res. 1983;  273 369-373
    CrossrefPubMedGoogle Scholar
  • 197 Brunetti L, Michelotto B, Orlando G, Vacca M. Leptin inhibits norepinephrine and dopamine release from rat hypothalamic neuronal endings.  Eur J Pharmacol. 1999;  372 237-240
    CrossrefPubMedGoogle Scholar
  • 198 Pothos E N, Creese I, Hoebel B G. Restricted eating with weight loss selectively decreases extracellular dopamine in the nucleus accumbens and alters dopamine response to amphetamine, morphine, and food intake.  J Neurosci. 1995;  15 6640-6650
    PubMedGoogle Scholar
  • 199 Szczypka M S, Rainey M A, Palmiter R D. Dopamine is required for hyperphagia in Lep(ob/ob) mice.  Nat Genet. 2000;  25 102-104
    PubMedGoogle Scholar
  • 200 Nonogaki K, Strack A M, Dallman M F, Tecott L H. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene.  Nat Med. 1998;  4 1152-1156
    PubMedGoogle Scholar
  • 201 Calapai G, Corica F, Corsonello A, Sautebin L, Di Rosa M, Campo G M, Buemi M, Mauro V N, Caputi A P. Leptin increases serotonin turnover by inhibition of brain nitric oxide synthesis.  J Clin Invest. 1999;  104 975-982
    PubMedGoogle Scholar
  • 202 Morimoto T, Yamamoto Y, Mobarakeh J I, Yanai K, Watanabe T, Yamatodani A. Involvement of the histaminergic system in leptin-induced suppression of food intake.  Physiol Behav. 1999;  67 679-683
    CrossrefPubMedGoogle Scholar
  • 203 Lecklin A, Hermonen P, Tarhanen J, Mannisto P T. An acute i. c. v. infusion of leptin has no effect on hypothalamic histamine and tele-methylhistamine contents in Wistar rats.  Eur J Pharmacol. 2000;  395 113-119
    CrossrefPubMedGoogle Scholar
  • 204 Hebebrand J, Van der Heyden J, Devos R, Kopp W, Herpertz S, Remschmidt H, Herzog W. Plasma concentrations of obese protein in anorexia nervosa.  Lancet. 1995;  346 1624-1625
    PubMedGoogle Scholar
  • 205 Grinspoon S, Gulick T, Askari H, Landt M, Lee K, Anderson E, Ma Z, Vignati L, Bowsher R, Herzog D, Klibanski A. Serum leptin levels in women with anorexia nervosa.  J Clin Endocrinol Metab. 1996;  81 3861-3863
    PubMedGoogle Scholar
  • 206 Hebebrand J, Blum W F, Barth N, Coners H, Englaro P, Juul A, Ziegler A, Warnke A, Rascher W, Remschmidt H. Leptin levels in patients with anorexia nervosa are reduced in the acute stage and elevated upon short-term weight restoration.  Mol Psychiatry. 1997;  2 330-334
    CrossrefPubMedGoogle Scholar
  • 207 Hebebrand J, Ballauff A, Hinney A, Herpertz S, Kopp W, Wewetzer C, Ziegler A, Blum W F, Remschmidt H. Die Gewichtsregulation im Rahmen der Anorexia nervosa unter besonderer Berücksichtigung der Leptinsekretion.  Nervenarzt. 1999;  70 31-40
    CrossrefPubMedGoogle Scholar
  • 208 Ferron F, Considine R V, Peino R, Lado I G, Dieguez C, Casanueva F F. Serum leptin concentrations in patients with anorexia nervosa, bulimia nervosa and non-specific eating disorders correlate with the body mass index but are independent of the respective disease.  Clin Endocrinol (Oxf). 1997;  46 289-293
    CrossrefPubMedGoogle Scholar
  • 209 Deuschle M, Blum W F, Englaro P, Schweiger U, Weber B, Pflaum C D, Heuser I. Plasma leptin in depressed patients and healthy controls.  Horm Metab Res. 1996;  28 714-717
    PubMedGoogle Scholar
  • 210 Antonijevic I A, Murck H, Frieboes R M, Horn R, Brabant G, Steiger A. Elevated nocturnal profiles of serum leptin in patients with depression.  J Psychiatr Res. 1998;  32 403-410
    CrossrefPubMedGoogle Scholar
  • 211 Brömel T, Blum W F, Ziegler A, Schulz E, Bender M, Fleischhaker C, Remschmidt H, Krieg J C, Hebebrand J. Serum leptin levels increase rapidly after initiation of clozapine therapy.  Mol Psychiatry. 1998;  3 76-80
    CrossrefPubMedGoogle Scholar
  • 212 Kraus T, Haack M, Schuld A, Hinze-Selch D, Kühn M, Uhr M, Pollmächer T. Body weight and leptin plasma levels during treatment with antipsychotic drugs.  Am J Psychiatry. 1999;  156 312-314
    PubMedGoogle Scholar
  • 213 Verrotti A, Basciani F, Morresi S, de Martino M, Morgese G, Chiarelli F. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid.  Neurology. 1999;  53 230-232
    PubMedGoogle Scholar
  • 214 Baptista T, Lacruz A, de Mendoza S, Mendoza Guillén J M, Silvera R, Angeles F, Mendoza M T, Hernández L. Body weight gain after administration of antipsychotic drugs:correlation with leptin, insulin and reproductive hormones.  Pharmacopsychiatry. 2000;  33 81-88
    Article in Thieme ConnectPubMedGoogle Scholar
  • 215 Cerami A, Ikeda Y, Le Trang N, Hotez P J, Beutler B. Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor).  Immunol Lett. 1985;  11 173-177
    CrossrefPubMedGoogle Scholar
  • 216 Langhans W, Hrupka B. Interleukins and tumor necrosis factor as inhibitors of food intake.  Neuropeptides. 1999;  33 415-424
    CrossrefPubMedGoogle Scholar
  • 217 Tisdale M J. Wasting in cancer.  J Nutr. 1999;  129 243-246
    PubMedGoogle Scholar
  • 218 Chang H R, Bistrian B. The role of cytokines in the catabolic consequences of infection and injury.  J Parenter Enteral Nutr. 1998;  22 156-166
    PubMedGoogle Scholar
  • 219 Tisdale M J. Biology of cachexia.  J Natl Cancer Inst. 1997;  89 1763-1773
    CrossrefPubMedGoogle Scholar
  • 220 Espat N J, Copeland E M, Moldawer L L. Tumor necrosis factor and cachexia: a current perspective.  Surg Oncol. 1994;  3 255-262
    CrossrefPubMedGoogle Scholar
  • 221 Hotamisligil G S, Shargill N S, Spiegelman B M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.  Science. 1993;  259 87-91
    CrossrefPubMedGoogle Scholar
  • 222 Lofgren P, van H V, Reynisdottir S, Naslund E, Ryden M, Rossner S, Arner P. Secretion of tumor necrosis factor-alpha shows a strong relationship to insulin-stimulated glucose transport in human adipose tissue.  Diabetes. 2000;  49 688-692
    PubMedGoogle Scholar
  • 223 Chedid L. Actions comparée de la prométhazine, de la chlorpromazine et de la cortisonenchez la souris recevant des doses mortelles d'une endotoxine bacterienne.  C R Seances Soc Biol Fil. 1954;  148 1039
    PubMedGoogle Scholar
  • 224 Descotes J, Evreux J C. Depressant effects of major tranquillizers on contact hypersensitivity to picryl chloride in the mouse.  Experientia. 1981;  37 1004-1005
    PubMedGoogle Scholar
  • 225 Roudebush R E, Berry P L, Layman N K, Butler L D, Bryant H U. Dissociation of immunosuppression by chlorpromazine and trifluoperazine from pharmacologic activities as dopamine antagonists.  Int J Immunopharmacol. 1991;  13 961-968
    CrossrefPubMedGoogle Scholar
  • 226 Erroi A, Fantuzzi G, Demitri M T, Echtenacher B, Gnocchi P, Isetta A, Ghezzi P. Protective effect of chlorpromazine on TNF-mediated hapten-induced irritant reaction.  Eur Cytokine Netw. 1995;  6 55-57
    PubMedGoogle Scholar
  • 227 Baker G A, Santalo R, Blumenstein J. Effect of psychotropic agents upon the blastogenic response of human t-lymphocytes.  Biol Psychiatry. 1977;  12 159-169
    PubMedGoogle Scholar
  • 228 Schleuning M, Brumme V, Wilmanns W. Inhibition of cyclosporin A/FK506 resistant, lymphokine-induced T-cell activation by phenothiazine derivatives.  Naunyn Schmiedebergs Arch Pharmacol. 1994;  350 100-103
    PubMedGoogle Scholar
  • 229 Won S J, Chuang Y C, Huang W T, Liu H S, Lin M T. Suppression of natural killer cell activity in mouse spleen lymphocytes by several dopamine receptor antagonists.  Experientia. 1995;  51 343-348
    PubMedGoogle Scholar
  • 230 Horwitz S B, Chia G H, Harracksingh C, Orlow S, Pifko-Hirst S, Schneck J, Sorbara L, Speaker M, Wilk E W, Rosen O M. Trifluoperazine inhibits phagocytosis in a macrophagelike cultured cell line.  J Cell Biol. 1981;  91 798-802
    CrossrefPubMedGoogle Scholar
  • 231 Watanabe S, Hirose M, Miyazaki A, Tomono M, Takeuchi M, Kitamura T, Namihisa T. Calmodulin antagonists inhibit the phagocytic activity of cultured Kupffer cells.  Lab Invest. 1988;  59 214-218
    PubMedGoogle Scholar
  • 232 Bertini R, Mengozzi M, Bianchi M, Sipe J D, Ghezzi P. Chlorpromazine protection against interleukin-1 and tumor necrosis factor-mediated activities in vivo.  Int J Immunopharmacol. 1991;  13 1085-1090
    PubMedGoogle Scholar
  • 233 Bertini R, Garattini S, Delgado R, Ghezzi P. Pharmalogical activities of chlorpromazine involved in the inhibition of tumour necrosis factor production in vivo in mice.  Immunology. 1993;  79 217-219
    PubMedGoogle Scholar
  • 234 Mengozzi M, Fantuzzi G, Faggioni R, Marchant A, Goldman M, Orencole S, Clark B D, Sironi M, Benigni F, Ghezzi P. Chlorpromazine specifically inhibits peripheral and brain TNF production, and up-regulates IL-10 production, in mice.  Immunology. 1994;  82 207-210
    PubMedGoogle Scholar
  • 235 Tarazona R, Gonzalez-Garcia A, Zamzami N, Marchetti P, Frechin N, Gonzalo J A, Ruiz-Gayo M, van Rooijen N, Martinez C, Kroemer G. Chlorpromazine amplifies macrophage-dependent IL-10 production in vivo.  J Immunol. 1995;  154 861-870
    PubMedGoogle Scholar
  • 236 Kim K H. Effects of antipsychotic drugs on cellular immunity in mice.  Yonsei Med J. 1986;  27 59-66
    PubMedGoogle Scholar
  • 237 Kaada B, Woie L. Effects of an angiotensin converting enzyme (ACE) inhibitor on plasma endorphin level.  Gen Pharmacol. 1990;  21 693-695
    PubMedGoogle Scholar
  • 238 Zinetti M, Galli G, Demitri M T, Fantuzzi G, Minto M, Ghezzi P, Alzani R, Cozzi E, Fratelli M. Chlorpromazine inhibits tumour necrosis factor synthesis and cytotoxicity in vitro.  Immunology. 1995;  86 416-421
    PubMedGoogle Scholar
  • 239 Pollmächer T, Fenzel T, Mullington J, Hinze-Selch D. The influence of clozapine treatment on plasma granulocyte colony-stimulating (G-CSF) levels.  Pharmacopsychiatry. 1997;  30 118-121
    PubMedGoogle Scholar
  • 240 Pollmächer T, Hinze-Selch D, Fenzel T, Kraus T, Schuld A, Mullington J. Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol.  Am J Psychiatry. 1997;  154 1763-1765
    PubMedGoogle Scholar
  • 241 Pollmächer T, Haack M, Schuld A, Kraus T, Hinze-Selch D. Effects of antipsychotic drugs on cytokine networks.  J Psychiatr Res. 2000;  34 369-382
    CrossrefPubMedGoogle Scholar
  • 242 Kushner R F. Bioelectrical impedance analysis: a review of principles and applications.  J Am Coll Nutr. 1992;  11 199-209
    CrossrefPubMedGoogle Scholar
  • 243 Lukaski H C, Bolonchuk W W, Hall C B, Siders W A. Validation of Tetrapolar Bioelectrical Impedance Method to Assass Human Body Composition.  J Appl Physiol. 1986;  60 1327-1332
    PubMedGoogle Scholar
  • 244 Wadden T A, Foster G D. Behavioral treatment of obesity.  Med Clin North Am. 2000;  84 441-461
    CrossrefPubMedGoogle Scholar
  • 245 Greenberg I, Chan S, Blackburn G L. Nonpharmacologic and pharmacologic management of weight gain.  J Clin Psychiatry. 1999;  60 Suppl 21 31-36
    PubMedGoogle Scholar
  • 246 Amdisen A. Drug-produced obesity: experiences with chlorpromazine, perphenazine, and clopentixol.  Danish Medical Bulletin. 1964;  11 182-189
    PubMedGoogle Scholar
  • 247 Goodall E, Oxtoby C, Richards R, Watkinson G, Brown D, Silverstone T. A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity.  Br J Psychiatry. 1988;  153 208-213
    PubMedGoogle Scholar
  • 248 Hinze-Selch D, Deuschle M, Weber B, Heuser I, Pollmächer T. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight.  Psychopharmacology (Berl). 2000;  149 163-169
    CrossrefPubMedGoogle Scholar
  • 249 Astrup A, Toubro S, Cannon S, Hein P, Madsen J. Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a double-blind, placebo-controlled study.  Metabolism. 1991;  40 323-329
    CrossrefPubMedGoogle Scholar
  • 250 McNeely W, Goa K L. Sibutramine. A review of its contribution to the management of obesity.  Drugs. 1998;  56 1093-1124
    CrossrefPubMedGoogle Scholar
  • 251 Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine.  Am J Med. 1999;  106 179-184
    CrossrefPubMedGoogle Scholar
  • 252 Bertino M, Beauchamp G K, Engelman K. Naltrexone, an Opioid Blocker, Alters Taste Perception and Nutrient Intake in Humans.  Am J Physiol. 1991;  261 R59-R63
    PubMedGoogle Scholar
  • 253 Levine A S, Billington C J. Opioids. Are they regulators of feeding?.  Ann N Y Acad Sci. 1989;  575 209-219
    PubMedGoogle Scholar
  • 254 Davidson M H, Hauptman J, DiGirolamo M, Foreyt J P, Halsted C H, Heber D, Heimburger D C, Lucas C P, Robbins D C, Chung J, Heymsfield S B. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.  JAMA. 1999;  281 235-242
    CrossrefPubMedGoogle Scholar
  • 255 Finer N, James W P, Kopelman P G, Lean M E, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.  Int J Obes Relat Metab Disord. 2000;  24 306-313
    CrossrefPubMedGoogle Scholar
  • 256 Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar H P, Krempf M. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.  Lancet. 1998;  352 167-172
    CrossrefPubMedGoogle Scholar
  • 257 Stoa-Birketvedt G, Paus P N, Ganss R, Ingebretsen O C, Florholmen J. Cimetidine reduces weight and improves metabolic control in overweight patients with type 2 diabetes.  Int J Obes Relat Metab Disord. 1998;  22 1041-1045
    CrossrefPubMedGoogle Scholar
  • 258 Stoa-Birketvedt G. Effect of cimetidine suspension on appetite and weight in overweight subjects.  BMJ. 1993;  306 1091-1093
    PubMedGoogle Scholar
  • 259 Sacchetti E, Guarneri L, Bravi D. H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients.  Biol Psychiatry. 2000;  48 167-168
    PubMedGoogle Scholar
  • 260 Heymsfield S B, Greenberg A S, Fujioka K, Dixon R M, Kushner R, Hunt T, Lubina J A, Patane J, Self B, Hunt P, McCamish M. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial.  JAMA. 1999;  282 1568-1575
    CrossrefPubMedGoogle Scholar
  • 261 Caro J F, Kolaczynski J W, Nyce M R, Ohannesian J P, Opentanova I, Goldman W H, Lynn R B, Zhang P L, Sinha M K, Considine R V. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance.  Lancet. 1996;  348 159-161
    CrossrefPubMedGoogle Scholar
  • 262 Fernstrom M H, Kupfer D J. Antidepressant-induced weight gain: a comparison study of four medications.  Psychiatry Res. 1988;  26 265-271
    CrossrefPubMedGoogle Scholar
  • 263 Frank E, Kupfer D J, Buhari A, McEachran A B, Grochocinski V J. Imipramine and weight gain during the long-term treatment of recurrent depression.  J Affect Disord. 1992;  26 65-72
    CrossrefPubMedGoogle Scholar

PD Dr. med T Pollmächer

Max-Planck-Institut für Psychiatrie

Kraepelinstr. 10
80804 München

Email: E-mail: topo@mpipsykl.mpg.de